1. Home
  2. ACRS vs AISP Comparison

ACRS vs AISP Comparison

Compare ACRS & AISP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • AISP
  • Stock Information
  • Founded
  • ACRS 2012
  • AISP 2006
  • Country
  • ACRS United States
  • AISP United States
  • Employees
  • ACRS N/A
  • AISP N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • AISP Blank Checks
  • Sector
  • ACRS Health Care
  • AISP Finance
  • Exchange
  • ACRS Nasdaq
  • AISP Nasdaq
  • Market Cap
  • ACRS 127.6M
  • AISP 107.6M
  • IPO Year
  • ACRS 2015
  • AISP N/A
  • Fundamental
  • Price
  • ACRS $1.14
  • AISP $3.64
  • Analyst Decision
  • ACRS Strong Buy
  • AISP Strong Buy
  • Analyst Count
  • ACRS 7
  • AISP 2
  • Target Price
  • ACRS $11.67
  • AISP $9.00
  • AVG Volume (30 Days)
  • ACRS 968.2K
  • AISP 706.7K
  • Earning Date
  • ACRS 05-06-2025
  • AISP 05-14-2025
  • Dividend Yield
  • ACRS N/A
  • AISP N/A
  • EPS Growth
  • ACRS N/A
  • AISP N/A
  • EPS
  • ACRS N/A
  • AISP N/A
  • Revenue
  • ACRS $18,720,000.00
  • AISP $23,050,213.00
  • Revenue This Year
  • ACRS N/A
  • AISP $34.30
  • Revenue Next Year
  • ACRS $425.96
  • AISP $59.47
  • P/E Ratio
  • ACRS N/A
  • AISP N/A
  • Revenue Growth
  • ACRS N/A
  • AISP 87.41
  • 52 Week Low
  • ACRS $0.95
  • AISP $1.90
  • 52 Week High
  • ACRS $5.17
  • AISP $8.44
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 27.21
  • AISP 44.32
  • Support Level
  • ACRS $1.05
  • AISP $3.15
  • Resistance Level
  • ACRS $1.23
  • AISP $3.95
  • Average True Range (ATR)
  • ACRS 0.11
  • AISP 0.34
  • MACD
  • ACRS -0.01
  • AISP -0.01
  • Stochastic Oscillator
  • ACRS 16.82
  • AISP 51.04

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About AISP Airship AI Holdings Inc.

Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where they need it, using a highly secure permission-based architecture.

Share on Social Networks: